NKNatalia Krzyżanowska

Natalia Krzyżanowska

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Natalia Krzyżanowska has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Integrated tissue and longitudinal ctDNA profiling reveal distinct genomic evolutionary trajectories associated with response to first-line immunotherapy and chemioimmunotherapy in advanced NSCLC patients

    by Marcin Nicoś, Natalia Galant, Natalia Krzyżanowska, Barbara Kuznar-Kaminska, Izabela Chmielewska, Tomasz Jankowski, Anna Grenda, Michał Gil, Pawel Krawczyk, Janusz Milanowski

    Background: Immune checkpoint inhibitors (ICIs) have become a central component of first-line treatment in advanced non-small cell lung cancer (NSCLC). Despite the implementation of predictive biomarkers such as PD-L1 expression on tumor cells, treatment response remains highly heterogeneous, and the mechanisms underlying durable clinical benefit and the evolution of therapy resistance are still poorly understood.Methods: We performed integrated longitudinal genomic profiling of 520 tumor tissue and liquid biopsy samples collected from 127 patients with advanced NSCLC treated with first-line pembrolizumab-based therapy. Low-pass whole-genome sequencing (lp-WGS) and targeted sequencing were used to characterize copy number alteration (CNA) dynamics, mutational processes, and clonal evolution associated with treatment response. Longitudinal circulating tumor DNA (ctDNA) analyses were integrated with baseline tumor tissue profiling to compare genomic trajectories between short- and long-responders.Results: Both short- and long-responders initially demonstrated transient molecular response characterized by broad CNA normalization and reduction of detectable variants during the first months of treatment. However, longitudinal analyses revealed major differences in evolutionary dynamics between response groups. Short responders demonstrated early shifts in subclonal architecture and rapid emergence of resistant clonal populations, whereas long responders maintained relative evolutionary stability with delayed diversification during therapy. Recurrent focal CNAs associated with therapy resistance included persistent amplification of the 3q22–q28 region harboring multiple oncogenic drivers, as well as alterations involving FGFR1, MYC, CCNE1, CDKN2A/B, and ICOSLG loci. Mutational analyses revealed enrichment of KRAS/STK11/KEAP1 alterations and DNA repair deficiency-associated mutational signatures in short responders, whereas long responders showed enrichment of APOBEC-associated mutagenesis and ZFHX3 alterations. Longitudinal TP53 variant allele frequency (VAF) dynamics further demonstrated persistent clonal turnover in short responders compared with a marked reduction of TP53-mutant burden in long responders.Conclusions: Our findings indicate that response to immunotherapy in advanced NSCLC is shaped not only by baseline molecular characteristics but also by distinct evolutionary trajectories developing under treatment pressure. Longitudinal ctDNA profiling enables dynamic monitoring of resistant tumor evolution and may support improved stratification of patients receiving immunotherapy.

  • Open Access

    When genetics meets immunology: the assessment of genetic and immunological backgrounds in advanced NSCLC patients treated with immunotherapy – preliminary study

    by Natalia Krzyżanowska, Marcin Nicoś, Kamila Wojas-Krawczyk, Paweł Krawczyk, Izabela Chmielewska, Tomasz Jankowski, Tomasz Kucharczyk, Magdalena Wójcik-Superczyńska, Anna Sroka-Bartnicka, Tomasz Stokowy, et al.

    Non-small-cell lung cancer treatment relies greatly on immunotherapy, especially in individuals without targetable mutations enabling the use of molecularly targeted therapies. Negative immune checkpoint inhibitors significantly contribute to improving patients’ survival and quality of life. Both programmed death ligand 1 expression on tumour cells and tumour mutational burden are used to predict the response to such treatment and qualify patients for therapy; however, in some cases, these biomarkers do not perform sufficiently well. Discovering new markers indicating resistance or response to immunotherapy would therefore enable clinicians to tailor the therapy course to the patient’s benefit. This paper aims to describe the genetic and immunological background of immunotherapy courses and identify factors potentially related to clinical benefit or lack of response to immunotherapy, using next-generation sequencing of tumour tissue and flow cytometry analysis of lymphocyte subpopulations in the peripheral blood of non-small cell lung cancer patients in a preliminary study.

  • Open Access

    Beyond BRCA1 and BRCA2 — a germline PALB2 deletion and CHEK2 substitution in a woman with breast cancer and family history of cancer

    by Natalia Krzyżanowska, Paweł Krawczyk, Kamila Wojas-Krawczyk, Łukasz Gajek, Adrian Obara

    Genes that encode proteins involved in DNA repair have been extensively studied in relation to tumorigenesis and cancer treatment. Many germline variants that significantly increase the risk of cancer development have been identified, with PALB2 and CHEK2 being among those genes of interest, as they influence the likelihood of cancer occurrence, such as breast and prostate cancer. This study presents a family with multiple cancer cases carrying germline variants in PALB2 (c.172_175del, p.Gln60Argfs) and CHEK2 (c.470T>C, p.Ile157Thr). In the individual in whom the variants were first discovered, early-onset breast cancer occurred. While one variant is considered pathogenic, the other remains questionable. This paper aims to describe the family’s characteristics and discuss the genetic alterations that contribute to tumor development among its members. Keywords: PALB2 CHEK2 germline mutation inherited cancer breast cancer

  • Open Access

    Application of Fourier transform infrared (FTIR) spectroscopy in liquid biopsy to predict the response to the first-line immunotherapy in non-small-cell lung cancer (NSCLC) patients

    by Natalia Galant, Marcin Nicoś, Maryna Khalavka, Natalia Krzyżanowska, Izabela Chmielewska, Barbara Kuźnar-Kamińska, Paweł Krawczyk, Anna Sroka-Bartnicka, Joanna Depciuch


  • Open Access

    T cell immunoglobulin and mucin-domain containing-3 (TIM-3), lymphocyte-activation gene 3 (LAG-3), and T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) — an update on emerging negative immune checkpoints in cancer treatment

    by Natalia Krzyżanowska

    Immunotherapy is currently one of the most important treatment options for patients with various cancers. It is predominantly based on immune checkpoint inhibitors (ICIs), which are supposed to reverse immune suppression caused by interactions of negative immune checkpoints with their ligands. Cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed death 1 (PD-1), and its ligand, programmed death ligand 1 (PD-L1) are the checkpoints targeted by antibodies registered in various types of cancer to enable effective anti-cancer immune response. Despite numerous possibilities, other molecules belonging to immune checkpoints — T cell immunoglobulin and mucin-domain containing-3 (TIM-3), lymphocyte-activation gene 3 (LAG-3), and T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT), are being extensively researched, mainly due to their role in cancer progression and resistance to immunotherapy. Recently, the first antibody against LAG-3 — relatlimab has been registered in melanoma, and many others are tested in the final stages of clinical trials. Thus, understanding their intricate functions and developing strategies to use them can create opportunities to apply immunotherapy in cancer treatment. This article describes their characteristics and potential role in solid-tumor treatment with TIM-3, LAG-3, and TIGIT molecules, which have been connected to tumor progression, poor survival, and poor prognosis in many tumor types. Keywords: TIM-3 LAG-3 TIGIT immunotherapy negative immune checkpoints solid tumors


  • Unlocking the potential: the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR) as biomarkers informing immunotherapy outcomes in lung cancer patients — single oncology center experience and literature review

    by Tomasz Jankowski, Natalia Krzyżanowska, Kamila Wojas-Krawczyk, Aleksandra Grzywna, Paweł Krawczyk, Izabela Chmielewska, Michał Szczyrek, Janusz Milanowski

    Introduction. The neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR), two promising biomarkers of effectiveness of cancer immunotherapy, have obtained great attention in recent years. The NLR and PLR are both simple and readily available markers derived from routine blood tests. It is postulated that integrating these biomarkers into clinical practice could facilitate monitoring immunotherapy effects. In this study, we retrospectively examined NLR and PLR values in non-small cell lung cancer patients (NSCLC) receiving second-line immunotherapy. Material and methods. The study group included 73 NSCLC patients: 38 men and 35 women. Twenty-three patients were diagnosed with squamous cell carcinoma (SqCC), and 50 patients with non-squamous cell carcinoma (non-SqCC). We assessed NLR and PLR values at immunotherapy initiation (NLR1, PLR1) and after 3 months of the follow-up (NLR2 and PLR2). These parameters were correlated with the clinical characteristics of patients, response to treatment, progression-free survival (PFS), and overall survival (OS). Results. The values of PLR1 and delta PLR were significantly higher in non-SqCC patients compared to SqCC patients. Other clinical and demographic factors did not influence the values of NLR1, NLR2, PLR2, or delta NLR. Medians of NLR1 and NLR2 were significantly lower in patients with controlled disease than in patients with disease progression. Patients with PFS longer than 12 months had a significantly lower median NLR2 than patients with PFS shorter than 1 year. A factor that significantly increased the risk of progression and death was a high NLR2 value. Conclusions. NLR and PLR represent promising biomarkers for monitoring immunotherapy effectiveness in cancer patients, which offer insights into the dynamic interplay between the host immune system and tumor biology. Further research is warranted to validate their utility in larger patient cohorts and standardize their incorporation into clinical practice. Keywords: non-small cell lung cancer predictive factors immunotherapy neutrophils-to-lymphocytes ratio platelet-to-lymphocyte ratio

  • Open Access

    New Thiosemicarbazide Derivatives with Multidirectional Biological Action

    by Patryk Lasek, Urszula Kosikowska, Przemysław Kołodziej, Grażyna Kubiak-Tomaszewska, Natalia Krzyżanowska, Tomasz Szostek, Marta Struga, Marcin Feldo, Anna Bogucka-Kocka, Monika Wujec

    Over the years, several new medicinal substances have been introduced for the treatment of diseases caused by bacteria and parasites. Unfortunately, due to the production of numerous defense mechanisms by microorganisms and parasites, they still pose a serious threat to humanity around the world. Therefore, laboratories all over the world are still working on finding new, effective methods of pharmacotherapy. This research work aimed to synthesize new compounds derived from 3-trifluoromethylbenzoic acid hydrazide and to determine their biological activity. The first stage of the research was to obtain seven new compounds, including six linear compounds and one derivative of 1,2,4-triazole. The PASS software was used to estimate the potential probabilities of biological activity of the newly obtained derivatives. Next, studies were carried out to determine the nematocidal potential of the compounds with the use of nematodes of the genus Rhabditis sp. and antibacterial activity using the ACCT standard strains. To determine the lack of cytotoxicity, tests were performed on two cell lines. Additionally, an antioxidant activity test was performed due to the importance of scavenging free radicals in infections with pathogenic microorganisms. The conducted research proved the anthelmintic and antibacterial potential of the newly obtained compounds. The most effective were two compounds with a 3-chlorophenyl substituent, both linear and cyclic derivatives. They demonstrated higher efficacy than the drugs used in treatment.


  • Open Access

    Efficacy of chemoimmunotherapy in a lung adenocarcinoma patient with mutations in the KRAS and STK11

    by Natalia Krzyżanowska, Paweł Krawczyk, Izabela Chmielewska, Tomasz Jankowski, Kamila Wojas-Krawczyk, Janusz Milanowski

    Immunotherapy is a groundbreaking treatment method when it comes to cancer, and this includes non-small-cell lung cancer (NSCLC). In NSCLC patients, immunotherapy is used in a form of immune checkpoint inhibitors (ICIs), and depending on the proportion of tumor cells with programmed death ligand 1 (PD-L1) expression on them, it can be administered either in monotherapy (≥ 50%) or in combination with chemotherapy (< 50%). In this article, we would like to present a case of a female patient with Kirsten Rat Sarcoma Virus (KRAS)-mutated lung adenocarcinoma who was responding to chemoimmunotherapy for a long time despite the presence of co-mutation in the Serine/Threonine Kinase 11 (STK11) gene, known to worsen immunotherapy outcomes. In this patient, another mutation was found – in the nibrin (NBN) gene, which is of uncertain relevance, but it presumably could be connected to a better outcome as it encodes proteins involved in DNA repair. Deficiency in DNA repair may be marked by homologous recombination deficiency (HRD), and there already exists some evidence of better immunotherapy efficacy in patients with HRD. Considering the above, further investigation and thorough genetic diagnostics in NSCLC patients are required to fully understand the background of immunotherapy response. Immunotherapy is a groundbreaking treatment method when it comes to cancer, and this includes non-small-cell lung cancer (NSCLC). In NSCLC patients, immunotherapy is used in a form of immune checkpoint inhibitors (ICIs), and depending on the proportion of tumor cells with programmed death ligand 1 (PD-L1) expression on them, it can be administered either in monotherapy (≥ 50%) or in combination with chemotherapy (< 50%). In this article, we would like to present a case of a female patient with Kirsten Rat Sarcoma Virus (KRAS)-mutated lung adenocarcinoma who was responding to chemoimmunotherapy for a long time despite the presence of co-mutation in the Serine/Threonine Kinase 11 (STK11) gene, known to worsen immunotherapy outcomes. In this patient, another mutation was found – in the nibrin (NBN) gene, which is of uncertain relevance, but it presumably could be connected to a better outcome as it encodes proteins involved in DNA repair. Deficiency in DNA repair may be marked by homologous recombination deficiency (HRD), and there already exists some evidence of better immunotherapy efficacy in patients with HRD. Considering the above, further investigation and thorough genetic diagnostics in NSCLC patients are required to fully understand the background of immunotherapy response.


  • Open Access

    Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?

    by Natalia Krzyżanowska, Kamila Wojas-Krawczyk, Janusz Milanowski, Paweł Krawczyk

    Currently, one of the leading treatments for non-small-cell lung cancer is immunotherapy involving immune checkpoint inhibitors. These monoclonal antibodies restore the anti-tumour immune response altered by negative immune checkpoint interactions. The most commonly used immunotherapeutics in monotherapy are anti-PD-1 and anti-PD-L1 antibodies. The effectiveness of both groups of antibodies has been proven in many clinical trials, which have translated into positive immunotherapeutic registrations for cancer patients worldwide. These antibodies are generally well tolerated, and certain patients achieve durable responses. However, given the resistance of some patients to this form of therapy, along with its other drawbacks, such as adverse events, alternatives are constantly being sought. Specifically, new drugs targeting already known molecules are being tested, and new potential targets are being explored. The aim of this paper is to provide an overview of the latest developments in this area.